Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 USD | -2.63% | -7.83% | -10.71% |
Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
Mar. 22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 185M | Sales 2025 * | 251M | Capitalization | 354M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | 23M | EV / Sales 2024 * | 1.91 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.41 x |
P/E ratio 2024 * |
-31
x | P/E ratio 2025 * |
16.9
x | Employees | 315 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.41% |
Latest transcript on Harrow, Inc.
1 day | -2.63% | ||
1 week | -7.83% | ||
Current month | -24.41% | ||
1 month | -16.67% | ||
3 months | +3.52% | ||
6 months | -28.52% | ||
Current year | -10.71% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 11-11-30 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Director/Board Member | 65 | Jan. 25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | Jan. 25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 10 | -2.63% | 449,827 |
24-04-24 | 10.27 | -0.48% | 406,228 |
24-04-23 | 10.32 | -2.64% | 661,080 |
24-04-22 | 10.6 | +1.44% | 587,408 |
24-04-19 | 10.45 | -3.69% | 681,281 |
Delayed Quote OTC Markets, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.71% | 354M | |
+25.63% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.11% | 233B | |
+5.34% | 201B | |
-9.94% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- HROW Stock